Uveal Melanoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Melanoma (1043)

Ocular Melanoma (111)

Cutaneous Melanoma (86)

Mucosal Melanoma (33)

Melanoma (1043)

Ocular Melanoma (111)

Cutaneous Melanoma (86)

Mucosal Melanoma (33)

›

HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	melphalan hepatic delivery system Sensitive: A1 - Approval melphalan hepatic delivery system Sensitive : A1	melphalan hepatic delivery system Sensitive: A1 - Approval melphalan hepatic delivery system Sensitive : A1
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
GPNMB expression	Uveal Melanoma	GPNMB expression	Uveal Melanoma	CDX-011 Sensitive: C2 – Inclusion Criteria CDX-011 Sensitive : C2	CDX-011 Sensitive: C2 – Inclusion Criteria CDX-011 Sensitive : C2
MBD4 mutation	Uveal Melanoma	MBD4 mutation	Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CXCL10 elevation	Uveal Melanoma	CXCL10 elevation	Uveal Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3
LDH elevation	Uveal Melanoma	LDH elevation	Uveal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
LDH elevation	Uveal Melanoma	LDH elevation	Uveal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
LDH-L	Uveal Melanoma	LDH-L	Uveal Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
DDX43 overexpression	Uveal Melanoma	DDX43 overexpression	Uveal Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3

Uveal Melanoma

Associations(106)

Associations
(106)